autologous blood and marrow transplantation - Blog Science ...

198 Chapter 4: Lymphoma
100
90
80
. 70
CO ' .
u. 60 -
Q
50 -
40 -
30 •
20 -
10 •
3 ^
0
A-Arm A; n-46, 60%
B-Arm B; n-46, 60%
100
90
80
70
60
50
40
30
20
10
A-Arm A; n-81, 65%
B-Arm B; n-63, 65%
12 36 48
Months
-J—i A
24 36 48 60 72
Months
100
90
80
70
CO „
u. 60
°-50 •
40 •
30 •
20 •
10
0
60 72
A-Arm A; n-61,46%
B-Arm B; n-63, 60%
—i A
24 36 48 60 72 84
Months
Figure 1. Estimated 6-year overall survival, disease-free survival (DFS), and progressionfree
survival (PFS) according to treatment arm (arm A, VACOP-B; arm B, VACOP-B plus
autoBMT).
nine patients. Arm B: low risk, six patients; low/intermediate risk, 23 patients;
intermediate-high risk, 27 patients; high risk, seven patients (Table 1). Because of
the low number of patients in low- and high-risk groups, patients with no negative
factors were combined with patients with one negative factor, and patients with
three negative factors were combined with patients with two negative factors. In
the combined low- plus low-/intermediate-risk groups, the 6-year statistical
analysis did not show any difference in terms of overall survival, DFS, and PFS
between arms A and B. In the combined intermediate-/high- plus high-risk groups,
the 6-year statistical analysis did not show any difference in terms of overall
survival between the two arms of patients. However, for DFS, a statistical
advantage was evident for arm B patients (48 vs. 87%, respectively; r°=0.008). A
positive trend was also observed for PFS in favor of the HDT plus autoBMT (37
vs. 65%, respectively; P=0.08) (Fig. 2).
DISCUSSION
The VACOP-B regimen as front-line therapy offers a good percentage of
complete remissions in aggressive NHL. This is in line with previous reports. 19
The
addition of a salvage non-cross-resistant chemotherapeutic protocol (DHAP) in
arm A or HDT plus autoBMT in arm B gives similar results for response rate.